Drugs · acquisition-cost intelligence
Diclofenac Sodium ER
diclofenac sodium· ingredient diclofenacAcetic acid derivatives and related substances· DICLOFENAC SODIUM 100 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.73145
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other diclofenac products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Diclofenac Sodium Delayed Release | $0.06665 | −$0.66480 |
| Diclofenac DR | $0.06665 | −$0.66480 |
| Aleve Arthritis Pain Gel | $0.08776 | −$0.64370 |
| Diclofenac Potassium | $0.09863 | −$0.63280 |
| Clofenax | $0.12486 | −$0.60660 |
| Diclofenac Sodium | $0.36949 | −$0.36200 |
| Diclofenac Sodium | $0.39681 | −$0.33460 |
| Diclofenac Sodium Delayed Release | $0.72051 | −$0.01090 |
Medicare Part D coverage · CY2026
On 308 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 28% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.